Eagle Veterinary Technology이글벳

Eagle Veterinary Technology is profitable on a trailing basis, but its shares have fallen about 30% over the past year.

The company makes and imports veterinary medicines for livestock and sells imported pet food, with trailing-twelve-month revenue of ₩44.7B and net income of ₩5.1B to H1 2026. Its share price is ₩3,000, near the lower half of its 52-week range of ₩2,705 to ₩4,840, and it pays no dividend. The data does not include any news headlines or analyst views on the business.

What stands out

• Trailing operating margin is about 10% and net margin about 11.3%, slightly above the 2025 full-year operating margin of 9.8%.
• Revenue grew 3.9% in 2025 after falling 2.5% in 2024, while operating income rose to ₩4.3B in 2025 from ₩3.5B in 2024.
• Valuation looks low on the data shown: P/E of 7.5, P/B of 0.7 and EV/EBITDA of 6.2, with a DCF base value of ₩4,279 (bear ₩2,734, bull ₩6,968).
• Balance sheet appears modest: liabilities are 24% of equity, but borrowings of ₩5.0B are close to cash of ₩6.1B.
• Foreign ownership rose from 1.4% to 2% over 60 days, while foreign and institutional investors were net sellers over the last 20 days.

What to watch

• The amended H1 2026 half-year report filed on 1 October 2026 and the next quarterly results, which are not yet in the data.
• Whether the company's cash dividend policy changes, since no dividend yield is currently paid.
• Dependence on raw materials largely sourced from China, which the profile names but the data does not quantify as a risk.